Integrated Smoking Cessation Treatment for Low Income Community Corrections

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01257490

Enrollment

689

Registered

2010-12-09

Start date

2009-10-31

Completion date

2014-03-31

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Cessation

Brief summary

This study recruited cigarette smokers under supervision in community corrections (e.g., probation, parole, drug courts, etc.) in the Birmingham, Alabama area. Smokers received 12 weeks of bupropion treatment and brief physician advice to quit smoking or 12 weeks of bupropion treatment and 4 sessions of intensive counseling around smoking cessation. The study was stratified on race such that equal proportions of African Americans and Caucasians were enrolled in the two study groups. It was hypothesized that smokers receiving intensive counseling will have higher quit rates compared to smokers receiving brief advice to quit.

Interventions

BEHAVIORALcounseling vs. advice

1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* At least 19 years or older * Enrolled in criminal justice community supervision (e.g., probation, parole, drug court, community corrections, etc) * Smoking at least 5 cpd for the past year * Maintained in an unrestricted environment (e.g., not currently in a correctional facility or treatment facility) living in the Birmingham Area and surrounding communities

Exclusion criteria

* Pregnant or nursing (all women in this study will be required to use an acceptable form of contraception throughout the administration of the medication) * Known sensitivity to Zyban or Wellbutrin * History of seizures * Current or prior anorexia or bulimia * Abrupt withdrawal from alcohol or benzodiazepines * Moderate to severe kidney problems * Moderate liver problems * Cognitive impairment such that they cannot provide informed consent

Design outcomes

Primary

Measure	Time frame
smoking cessation	3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026